drugset

drugset / Trial / NCT05060263

A Study of of HOT1030 in Patients With Advanced Solid Tumors

NCT05060263 ↗

Phase 1 Unknown 42 enrolled Huabo Biopharm Co., Ltd.

Non-randomizedSingle-groupOpen-labelHealth-services research

Summary

A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HOT-1030 in Patients with Advanced Solid Tumors

Timeline

Start: 2021-03-12
Primary completion: 2023-06-30
Completion: 2023-06-30

Publications

Singh R, Kim YH, Lee SJ, Eom HS, Choi BK. 4-1BB immunotherapy: advances and hurdles. Exp Mol Med. 2024 Feb;56(1):32-39. doi: 10.1038/s12276-023-01136-4. Epub 2024 Jan 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HOT-1030	Monoclonal antibody	—	Intravenous

Indications